Steven L. Fasman
Net Worth
Last updated:
What is Steven L. Fasman net worth?
The estimated net worth of Mr. Steven L. Fasman is at least $22,595,429 as of 24 Aug 2023. He has earned $13,355,429 from insider trading and has received compensation worth at least $9,240,000 in Catalent, Inc..
What is the salary of Steven L. Fasman?
Mr. Steven L. Fasman salary is $1,320,000 per year as Senior Vice President, Gen. Counsel & Corporation Sec. in Catalent, Inc..
How old is Steven L. Fasman?
Mr. Steven L. Fasman is 62 years old, born in 1963.
What stocks does Steven L. Fasman currently own?
As insider, Mr. Steven L. Fasman owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Catalent, Inc. (CTLT) | Senior Vice President, Gen. Counsel & Corporation Sec. | 73,789 | $0 | $0 |
What does Catalent, Inc. do?
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Steven L. Fasman insider trading
Catalent, Inc.
Mr. Steven L. Fasman has made 20 insider trades between 2018-2023, according to the Form 4 filled with the SEC. Most recently he sold 817 units of CTLT stock worth $36,479 on 24 Aug 2023.
The largest trade he's ever made was exercising 34,714 units of CTLT stock on 4 Oct 2021. As of 24 Aug 2023 he still owns at least 73,789 units of CTLT stock.
Catalent key executives
Catalent, Inc. executives and other stock owners filed with the SEC:
- Mr. Alessandro Maselli (53) Pres & Chief Operating Officer
- Mr. John R. Chiminski (61) Chairman & Chief Executive Officer
- Mr. Steven L. Fasman (62) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Thomas P. Castellano (45) Senior Vice President & Chief Financial Officer
- Ms. Karen A. Flynn (62) Chief Commercial Officer